Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) was characterized as an autoimmune condition with the production of antiphospholipid antibodies (aPL) associated with thrombosis and morbidity in pregnancy. The prevalence of aPL in the population ranges from 1% to 5% in patients with APS. The hypotheses regarding pat...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hospital de Clínicas de Itajubá
2019-11-01
|
Series: | Revista Ciências em Saúde |
Subjects: | |
Online Access: | http://186.225.220.186:7474/ojs/index.php/rcsfmit_zero/article/view/892 |
id |
doaj-009a92b7aa68419ea847f3e0e6bbb357 |
---|---|
record_format |
Article |
spelling |
doaj-009a92b7aa68419ea847f3e0e6bbb3572020-11-25T03:59:42ZengHospital de Clínicas de ItajubáRevista Ciências em Saúde2236-37852019-11-0194374210.21876/rcshci.v9i4.892892Antiphospholipid SyndromeThaís da Silva Santos0Izabel Galhardo Demarchi1Tatiane França Perles Mello2Jorge Juarez Vieira Teixeira3Maria Valdrinez Campana Lonardoni4Doutoranda do Programa de Pós-graduação em Biociências e Fisiopatologia da Universidade Estadual de Maringá, Maringá, Paraná, Brasil.Docente do Departamento de Análises Clinicas da Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brasil.Doutora pelo Programa de Pós-graduação em Biociências e Fisiopatologia da Universidade Estadual de Maringá, Maringá, Paraná, Brasil.Docente do Programa de Pós-graduação em Biociências e Fisiopatologia e do Departamento de Análises Clínicas e Biomedicina da Universidade Estadual de Maringá, Maringá, Paraná, Brasil.Docente do Programa de Pós-graduação em Biociências e Fisiopatologia e do Departamento de Análises Clínicas e Biomedicina da Universidade Estadual de Maringá, Maringá, Paraná, Brasil.Antiphospholipid syndrome (APS) was characterized as an autoimmune condition with the production of antiphospholipid antibodies (aPL) associated with thrombosis and morbidity in pregnancy. The prevalence of aPL in the population ranges from 1% to 5% in patients with APS. The hypotheses regarding pathophysiological mechanisms are strongly related to binding proteins and antiphospholipid antibodies. The exact mechanisms by which they lead to clinical manifestations appear to be heterogeneous, but it is believed which aPL contribute to the cellular activation/coagulation, and so cause the thrombotic events. The treatment of APS should be an individual character and several factors should be taken into accounts, such as a number of antibodies, the age of the patient and the history of thrombotic events.http://186.225.220.186:7474/ojs/index.php/rcsfmit_zero/article/view/892antiphospholipid antibodiesantiphospholipid syndromeautoimmune diseasespregnancy complications |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Thaís da Silva Santos Izabel Galhardo Demarchi Tatiane França Perles Mello Jorge Juarez Vieira Teixeira Maria Valdrinez Campana Lonardoni |
spellingShingle |
Thaís da Silva Santos Izabel Galhardo Demarchi Tatiane França Perles Mello Jorge Juarez Vieira Teixeira Maria Valdrinez Campana Lonardoni Antiphospholipid Syndrome Revista Ciências em Saúde antiphospholipid antibodies antiphospholipid syndrome autoimmune diseases pregnancy complications |
author_facet |
Thaís da Silva Santos Izabel Galhardo Demarchi Tatiane França Perles Mello Jorge Juarez Vieira Teixeira Maria Valdrinez Campana Lonardoni |
author_sort |
Thaís da Silva Santos |
title |
Antiphospholipid Syndrome |
title_short |
Antiphospholipid Syndrome |
title_full |
Antiphospholipid Syndrome |
title_fullStr |
Antiphospholipid Syndrome |
title_full_unstemmed |
Antiphospholipid Syndrome |
title_sort |
antiphospholipid syndrome |
publisher |
Hospital de Clínicas de Itajubá |
series |
Revista Ciências em Saúde |
issn |
2236-3785 |
publishDate |
2019-11-01 |
description |
Antiphospholipid syndrome (APS) was characterized as an autoimmune condition with the production of antiphospholipid antibodies (aPL) associated with thrombosis and morbidity in pregnancy. The prevalence of aPL in the population ranges from 1% to 5% in patients with APS. The hypotheses regarding pathophysiological mechanisms are strongly related to binding proteins and antiphospholipid antibodies. The exact mechanisms by which they lead to clinical manifestations appear to be heterogeneous, but it is believed which aPL contribute to the cellular activation/coagulation, and so cause the thrombotic events. The treatment of APS should be an individual character and several factors should be taken into accounts, such as a number of antibodies, the age of the patient and the history of thrombotic events. |
topic |
antiphospholipid antibodies antiphospholipid syndrome autoimmune diseases pregnancy complications |
url |
http://186.225.220.186:7474/ojs/index.php/rcsfmit_zero/article/view/892 |
work_keys_str_mv |
AT thaisdasilvasantos antiphospholipidsyndrome AT izabelgalhardodemarchi antiphospholipidsyndrome AT tatianefrancaperlesmello antiphospholipidsyndrome AT jorgejuarezvieirateixeira antiphospholipidsyndrome AT mariavaldrinezcampanalonardoni antiphospholipidsyndrome |
_version_ |
1724453414402785280 |